Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal clear cell carcinoma in our single center.

目的评价单中心舒尼替尼治疗转移性肾脏透明细胞癌的疗效和安全性。

youdao

Cox proportional-hazards analysis of progression-free survival according to baseline characteristics favored sunitinib in all subgroups studied.

在研究的所有亚组中，根据基线特征进行的PFS的Cox风险比例分析均有利于舒尼替尼。

youdao

Sunitinib and capecitabine doses were escalated in serial patient cohorts.

在这些患者中舒尼替尼和卡培他滨的剂量逐步递增。

youdao

"Other patients requesting funding for Sunitinib will still be assessed and considered in line with the PCT's standard protocols and procedures, " a statement said.

BBC: Cancer patient wins drugs battle

Hampshire PCT said the National Institute for Health and Clinical Excellence (Nice) currently recommends that Sunitinib is not used for the treatment of advanced and metastatic renal cell carcinoma (kidney cancer).

BBC: Woman in postcode drugs lottery

To date, Sutent (Sunitinib) has not been approved.

BBC: NEWS | UK | England | Cornwall | Trust refuses to fund cancer drug